Features

  • No dilation required, enhancing patient comfort
  • Short test time—only three minutes per patient
  • No interpretation and minimal training necessary
  • Immediate results provided on the device and in a PDF report
  • Portable, handheld device goes wherever patients with diabetes receive care

Product Specifications

Connects to EMR? Yes


Product Warranty: 1-Year
Specifications are for a 'typical' configuration. Click on any part number link to see part number specific details.

Top FAQs

View All FAQs

Top Documents

View All Documents

In just three minutes, you can comfortably screen for vision-threatening diabetic retinopathy wherever patients receive care.


Screen for vision-threatening diabetic retinopathy in just three minutes wherever patients with diabetes receive care—whether in primary care, a specialist setting, a pharmacy, or even a remote healthcare screening event. No advanced clinical training is required to perform the test or read the results. RETeval-DR offers significant time savings for both patients and physicians—especially when compared with having to make a separate appointment.

RETeval_Primary-Care-wborder

PRIMARY CARE

RETeval_Eye-Care_wborder

EYE CARE

RETeval_Pharmacy_wborder

PHARMACY

RETeval_Outreach_wborder

OUTREACH

RETeval-DR—Objective Screening for Vision-Threatening Diabetic Retinopathy

RETeval-DR is designed for healthcare providers who want to improve management of their patients with diabetes.

RETeval-DR can safely identify patients at low risk for blindness from diabatic retinopathy with 99.2% negative predictive value*, thereby allowing eye care providers to focus more time on patients with vision-threatening diabetic retinopathy.

* Multi-center, cross-sectional, 500 subject, clinical calibration / validation study of RETeval device in patients with diabetic retinopathy, 2014. Principal Investigator: Stephen R. Fransen, MD, Chief Medical Officer, Inoveon Corporation.
Sensor Strip

Unique Electroretinograph (ERG) Technology Made Simple

ERG is an instrument for measuring the electrical response of the retina to light stimulation—a fundus image is not required. Similar to an ECG, electrical activity of the retina is magnified and recorded as waves with patented non-invasive RETeval-DR Sensor Strips that comfortably rest below each eye. Signals from a diseased retina are reduced in size and slower than normal.

Welch Allyn VISION FOR ALL

Diabetic retinopathy is the leading cause of blindness among working-age adults. However, with early detection and treatment, most cases can be prevented.

The Welch Allyn Vision For All initiative is focused on delivering frontline solutions that will help to reduce or eliminate some of the leading causes of preventable blindness and vision-threatening conditions. This effort is dedicated to improving patient access to vision-saving technology by providing simple, affordable, advanced screening solutions to primary care physicians and eye care specialists.

 

RETeval™ and RETeval-DR™ are trademarks of LKC Technologies, Inc.
Tragically,documented compliance with vision-saving annual exams is often less than 50%

TRAGICALLY, DOCUMENTED COMPLIANCE WITH VISION-SAVING ANNUAL EXAMS IS OFTEN LESS THAN 50%.

With early, detection, 95% of vision loss cases can be prevented.

WITH EARLY DETECTION, 95% OF VISION LOSS CASES CAN BE PREVENTED.

Complete this form to learn more and schedule a demo

*
*
*
*
*
*
*
*
*